WisdomTree Global SmallCap Dividend Fund·Financial Services

(all amounts are in Canadian dollars) Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share Six months ended January 31, 2026, net loss of $3.8 million dollars, ($1.37) per share Cash as of January 31, 2026, $1.3 million; Company remains debt-free Reverse split of our common shares at ratio of sixty to one effected on January 22, 2026 Thykamine™ radiodermatitis prevention pivotal clinical study as a first priority for the Company Company continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™'s mechanism of action Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer reviewed journal, Biomedicines . QUÉBEC, March 25, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and six months ended January 31, 2026.

QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK.

QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two recent patent applications and is now a core component of the Company's long-term intellectual property and patent strategy. This fingerprint will be systematically incorporated into all future Thykamine™-related patent filings.

Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced additional preclinical results from its previously reported STAMTM mouse model in vivo study of metabolic dysfunction–associated steatohepatitis (MASH). These new data provide gene expression evidence supporting the anti-MASH, anti-inflammatory and anti-fibrotic effects of Thykamine™ observed in the liver.

Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary fibrosis QUÉBEC, Feb. 10, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of pulmonary fibrosis. The study investigated the effects of Thykamine™ in bleomycin-induced pulmonary fibrosis (IPF) mouse model, a widely used preclinical tool for studying idiopathic pulmonary fibrosis (IPF) pathophysiology and testing antifibrotic therapies.

QUÉBEC, Feb. 2, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed Dennis Turpin as Chief Financial Officer of the Company, effective today. Mr. Turpin currently serves and will remain on the Board of Directors of the Company.
The investment seeks to track the price and yield performance of the WisdomTree Global SmallCap Dividend Index. The fund will invest at least 80% of its total assets in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a fundamentally weighted index that consists of small-capitalization companies selected from the WisdomTree Global Dividend Index, which defines the dividend-paying universe of companies in the United States, developed countries, and emerging markets throughout the world. The fund is non-diversified.
Financial Services
Asset Management - Global
2021-09-28
0.00
Market Peers





